Has Ashley Magovern, MD received payments from drug or device companies?

Yes. Drug and device makers reported $33,368 in general payments to Ashley Magovern, MD across 301 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashley Magovern, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashley Magovern, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashley Magovern, MD

Dermatology · Manhattan Beach, CANPI 1770761207

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,130 of the $33,368 with a category attached, or 72.3%. AbbVie accounts for 84.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2020 at $16,387 and has fallen 95.7% since, to $697 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,368in general payments, 2019–2025

Across 301 payments — averaging $110.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$28K
Merz North America, Inc.$881
Sanofi$760
Galderma Laboratories, L.p.$682
Biofrontera Inc.$603
Sun Pharmaceutical Industries Inc.$234
plus $2K from 26 others

What the payments were for

Consulting fees$24,13072%
Speaking & faculty fees$3501%
Travel & lodging$2,5598%
Food & beverage$6,32919%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	96	$28,170
Merz North America, Inc.	8	$881
Sanofi	27	$760
Galderma Laboratories, L.p.	38	$682
Biofrontera Inc.	10	$603
Sun Pharmaceutical Industries Inc.	10	$234
Incyte Corporation	8	$207
Johnson & Johnson	8	$192
Almirall LLC	9	$172
LEO Pharma Inc.	9	$167
Regeneron Healthcare Solutions, Inc.	7	$162
Ortho Dermatologics, A Division Of Bausch Health US, LLC	7	$143
Pfizer	6	$130
EPI Health, LLC	6	$104
Journey Medical Corporation	6	$97
Sandoz	5	$95
Mayne Pharma Commercial LLC	15	$64
UCB, Inc.	2	$61
Sebela Pharmaceuticals Inc.	3	$56
Medimetriks Pharmaceuticals, Inc.	2	$51
VYNE Pharmaceuticals Inc.	3	$47
Novartis	2	$47
Bristol Myers Squibb	2	$44
Aclaris Therapeutics, Inc.	2	$32
Prugen, Inc. Pharmaceuticals	3	$27
E.r. Squibb & Sons, L.L.C.	1	$23
Arcutis Biotherapeutics, Inc.	1	$22
DUSA Pharmaceuticals, Inc.	1	$21
Solta Medical, A Division Of Bausch Health US, LLC	1	$21
Revance Therapeutics, Inc.	1	$20
Lilly USA, LLC	1	$16
Mission Pharmacal Company	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX COSMETIC$26,717
XEOMIN$589
AMELUZ$350
BF-RhodoLED$350
XEPI$350
BOTOX$125

How this compares

$33,368 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024

$224,391

Medicare patients

393

Services billed

9,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	17	$1,295

Paid to pharmacies, not to this prescriber.

Other dermatology in Manhattan Beach

Michelle EhrlichManhattan Beach$735K
Glynis AblonManhattan Beach$151K
Paul YamauchiSanta Monica$2.9M
Jennifer SoungSanta Ana$2.8M
Robert GreenbergLivermore$2.6M
Neal BhatiaSan Diego$2.5M
April ArmstrongLos Angeles$2.3M
Jeffrey CrowleyBakersfield$2.1M
Jashin WuCorona$2M
Raja SivamaniSacramento$1.9M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →